

# Endovascular Pharmacology

**A**lthough frequently not of great interest to the endovascular physician, especially compared to new technology in medical devices, the use of various pharmacologic agents during the course of vascular intervention can be just as important as the device itself, if not more. Because of this significance, this issue of *Endovascular Today* focuses on pharmacology for endovascular procedures.

Colleen Johnson, MD, and Leila Mureebe, MD, provide us with an overview of anticoagulation in peripheral interventions, as well as a listing of the relevant pharmaceuticals. Gerald Zemel, MD, discusses why anticoagulation during interventional procedures is important and highlights the potential benefits of newer agents. Emile R. Mohler, MD, delves into the science behind lipid therapy and explains some of its more practical elements. Also, James A.M. Smith, MD, acquaints us with the specifics of the vasopressors dopamine and phenylephrine, which are commonly used in conjunction

with carotid angioplasty and stenting.

This issue also contains our annual sub-feature on closure devices. We are once again fortunate to have Zoltan Turi, MD, provide his yearly update on closure devices and the technology available to interventionists. Gary S. Roubin, MD, expands on the potential value of these devices, describing why rapid ambulation after CAS

patients results in better outcomes. Finally, David H. Deaton, MD, and colleagues present their experience with percutaneous EVAR utilizing closure devices.

Our Society Update department features two very important articles. The first, an interview with Frank J. Veith, MD, explores the current vascular board certification situation, a controversial

topic within organized surgery and vascular surgery. The second article presents the status of the Society of Interventional Radiology (SIR), which is just completing its annual meeting.

As always, we hope this issue will bring practical value to your practice of endovascular therapy. ■



A handwritten signature in black ink that reads "Barry T. Katzen MD". The signature is written in a cursive, flowing style.

Barry T. Katzen, MD  
Chief Medical Editor